












2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Ailles, Laurie University Health Network	The role of PRMT1 in clear cell renal cell carcinoma	\$ 120,000/ 2 years
Alfieri, Carolina CHU Sainte-Justine	A humanized antibody for prevention of Epstein-Barr virus infection and associated cancers in pediatric transplant patients	\$ 119,771/ 2 years <i>Funded in partnership with the C17 Council</i> 
Ardolino, Michele Ottawa Hospital Research Institute	The immune checkpoint receptor LAG3 suppresses Natural Killer cells against cancer	\$ 120,000/ 2 years <i>Funded in partnership with the University of Ottawa and the Ottawa Hospital Research Institute</i>  
Aronson, Kristan Queen's University	Shift work as a carcinogen for breast cancer: melatonin, and circadian gene methylation among female hospital employees	\$ 120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i>  





2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Audet-Walsh, Etienne</i> Centre de recherche du CHU de Québec - Université Laval	Deciphering the role of KLF5 and NFYA in prostate cancer	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
<i>Auer, Rebecca</i> Ottawa Hospital Research Institute	Targeting surgery-induced myeloid derived suppressor cell inhibition of natural killer cells to prevent cancer recurrence in the postoperative period	\$ 119,370/ 2 years
<i>Baron, Christian</i> Université de Montréal	Prevention of gastric cancer by targeting the Helicobacter pylori type IV secretion system	\$ 120,000/ 2 years <i>Funded in partnership with the Charles Bowers Memorial Fund</i>  Charles Bowers Memorial Fund
<i>Basik, Mark</i> Lady Davis Institute	Targeting chemotherapy resistance in triple-negative breast cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Quebec Breast Cancer Foundation</i> 




2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Bathe, Oliver University of Calgary	Functional and molecular characterization of a novel variant of ovarian cancer	\$ 119,937/ 2 years
Beauséjour, Christian CHU-SJ - Université de Montréal	Improved tumour immunotherapy using senolytic drugs	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
Boucher, Marie-Josée Université de Sherbrooke	TFEB limits the accumulation of DNA damage to support pancreatic cancer cell growth	\$ 120,000/ 2 years <i>Funded in partnership with the Charlotte Legaré Memorial Fund</i> 
Bridle, Byram W. University of Guelph	Treatment of osteosarcoma lung metastases with an infected cancer cell vaccine	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 



2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Cairncross, Gregory</i> University of Calgary	Preventing the emergence of temozolomide resistance in glioblastoma	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i>  CIHR IRSC Canadian Institutes of Health Research / Institut de recherche en santé du Canada
<i>Côté, Jean-François</i> Institut de recherches cliniques de Montréal	Targeting the HectD1 /ACF7 signalling axis in breast cancer progression	\$ 120,000/ 2 years <i>Funded in partnership with the Rina Primeau Memorial Fund</i>  Rina Primeau Memorial Fund
<i>Cote, Jocelyn</i> University of Ottawa	A role for RNA-binding protein RALY in breast cancer	\$ 120,000/ 2 years <i>Funded in partnership with the University of Ottawa</i>  uOttawa
<i>Daniel, Juliet</i> McMaster University	Roles of the transcription factor Kaiso in intestinal inflammation and colon cancer	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i>  CIHR IRSC Canadian Institutes of Health Research / Institut de recherche en santé du Canada



2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Diamandis, Phedias</i> Princess Margaret Cancer Centre, University Health Network	Proteomic resolution of inter- and intra- tumoural heterogeneity in IDH-wild type glioblastoma	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
<i>Dick, Fred</i> Western University	Growth and survival mechanisms in ovarian cancer metastasis	\$ 120,000/ 2 years
<i>Garzia, Livia</i> Research Institute of the McGill University Health Centre	Targeting CCL2-CCR2 axis in metastatic medulloblastoma	\$ 119,830/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
<i>Gee, Stephen</i> University of Ottawa	Towards inhibiting breast cancer metastasis by targeting diacylglycerol kinase iota-RhoC interactions	\$ 120,000/ 2 years <i>Funded in partnership with the University of Ottawa</i> 



2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Gévry, Nicolas</i> Université de Sherbrooke	Targeting the NR5A2 nuclear receptor gene expression program in prostate cancer	\$ 120,000/ 2 years
<i>Gregorieff, Alex</i> Research Institute of the McGill University Health Centre	Dissecting the role of Yap-regulated clusterin in colorectal cancer	\$ 120,000/ 2 years
<i>Hammond, James</i> University of Alberta	SLC43A3 as a novel biomarker for the therapeutic efficacy of 6-mercaptopurine in acute lymphoblastic leukemia	\$ 120,000/ 2 years
<i>Han, Kathy</i> Princess Margaret Cancer Centre (PM), University Health Network (UHN)	Circulating HPV DNA as a biomarker of response in patients with locally advanced cervical cancer treated with definitive chemoradiation	\$ 120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i>  



2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Hombach-Klonisch, Sabine</i> University of Manitoba	The unfolded protein response (UPR) in early brain metastasis	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
<i>Huang, Sidong</i> McGill University	Uncovering tumour-intrinsic effectors and regulators of PD-L1 in triple-negative breast cancer	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
<i>Jones, Nina</i> University of Guelph	Investigating the role of Nck signaling in metastatic breast cancer	\$ 120,000/ 2 years
<i>Kassouf, Wassim</i> McGill University Health Center	Unravel key factors to optimize combination of radiation and immunotherapy to improve bladder-organ preservation treatment in muscle-invasive bladder cancer	\$ 120,000/ 2 years

2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Khalili, Korosh</i> University Health Network (PMCC)	Advancing the local staging of pancreatic ductal adenocarcinoma through high-resolution ultrasound: A pilot study	\$ 86,065 / 2 years <i>Funded in partnership with the Charlotte Legare Memorial Fund</i>  Charlotte Légaré Memorial Fund
<i>Klonisch, Thomas</i> University of Manitoba	Highly selective targeting of ABL kinase in patient-derived brain tumour initiating cells	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i>  CIHR IRSC Canadian Institutes of Health Research / Institut de recherche en santé du Canada
<i>Laverdière, Isabelle</i> Université Laval	Pharmacogene methylation profiling during childhood acute lymphoblastic leukemia treatment	\$ 120,000/ 2 years
<i>Lavoie, Josée N.</i> Université Laval, Centre de recherche du CHU de Québec, Oncologie	Deciphering mechanical stress-induced nuclear envelope remodeling in tumor cells	\$ 120,000/ 2 years


2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Lehner, Richard University of Alberta	Inhibiting cancer growth by modulating lipoprotein metabolism	\$ 120,000/ 2 years
Lesage, Sylvie Hôpital Maisonneuve-Rosemont	p53 mutations in NK cells impede the anti-tumour immune response	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
Lesage, Sylvie Hôpital Maisonneuve-Rosemont	Evaluating the impact of immunosuppressive drugs on the therapeutic efficacy of human DN T cells	\$ 120,000/ 2 years
Mann, Koren Lady Davis Institute for Medical Research	Tungsten-induced leukemogenesis	\$ 120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i> 




2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Marcil, Valérie</i> Research Center of Sainte-Justine UHC and Université de Montréal	Gut microbiota and pediatric cancer: filling the gap	\$ 119,960/ 2 years
<i>Maréchal, Alexandre</i> Université de Sherbrooke	Identification of the prerequisites and actors of the break-induced replication fork repair pathway	\$ 120,000/ 2 years
<i>Melichar, Heather</i> CR-Hôpital Maisonneuve-Rosemont / Université de Montréal	Aberrant expression of terminal deoxynucleotidyl transferase as a novel biomarker for the efficacy of checkpoint blockade immunotherapy	\$ 120,000/ 2 years
<i>Meloche, Sylvain</i> Université de Montréal	Role of ERK3 MAP kinase signaling in breast tumour initiating cells and cancer progression	\$ 120,000/ 2 years


2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<p><i>Mercier, Francois</i> Lady Davis Institute of the Jewish General Hospital</p>	<p>Identification of in vivo regulators of leukemic growth</p>	<p>\$ 120,000/ 2 years</p> <p><i>Funded in partnership with the CIHR Institute of Cancer Research</i></p> 
<p><i>Muller, William</i> McGill University</p>	<p>Role of an alternative splice isoform of ErbB2 in tumor progression</p>	<p>\$ 120,000/ 2 years</p>
<p><i>Mulligan, Lois</i> Cancer Research Institute at Queen's University</p>	<p>Establishing novel mechanisms of RET receptor-driven oncogenicity</p>	<p>\$ 120,000/ 2 years</p>
<p><i>Nathan, Paul</i> The Hospital for Sick Children</p>	<p>Performance and cost-effectiveness of a prediction tool to identify cancer predisposition syndromes in children with cancer</p>	<p>\$ 120,000/ 2 years</p>



2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<p><i>Notta, Faiyaz</i> Princess Margaret Cancer Centre, University Health Network</p>	Chemoresistance in pancreatic cancer	<p>\$ 120,000/ 2 years</p> <p><i>Funded in partnership with the Charlotte Legare Memorial Fund</i></p> 
<p><i>Paliouras, Miltiadis</i> Lady Davis Institute for Medical Research - Jewish General Hospital</p>	Targeting HER2 positive breast cancer using photo-ablative directed nanoparticles	<p>\$ 120,000/ 2 years</p> <p><i>Funded in partnership with CURE Foundation</i></p> 
<p><i>Parent, Marie-Elise</i> Institut national de la recherche scientifique (INRS), Université du Québec</p>	Potential predictors of prostate cancer development	<p>\$ 56,831/ 1 year</p> <p><i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i></p> 
<p><i>Pasdar, Manijeh</i> University of Alberta</p>	Investigating the therapeutic potential of plakoglobin-p53 interaction	<p>\$ 120,000/ 2 years</p>



2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Pause, Arnim</i> McGill University	Role of FLCN/AMPK/TFEB axis in breast cancer metabolic adaptation and metastatic progression	\$ 120,000/ 2 years
<i>Pelka, Peter</i> University of Manitoba	The role of Nek9 in cellular transformation and regulation of p53 target gene expression	\$ 120,000/ 2 years
<i>Pin, Christopher</i> The University of Western Ontario	Defining the epigenetic mechanisms underlying pancreatic ductal adenocarcinoma	\$ 120,000/ 2 years <i>Funded in partnership with the Rob Lutterman Memorial Fund</i>  Rob Lutterman Memorial Fund
<i>Rodier, Francis</i> Université de Montréal, CRCHUM	Molecular dissection of therapy-induced senescence during metastatic prostate cancer treatment	\$ 120,000/ 2 years



2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Roskelley, Calvin</i> University of British Columbia	The role of the podocalyxin complex in collective breast tumour cell invasion	\$ 120,000/ 2 years
<i>Shateri Najafabadi, Hamed</i> McGill University	Modulation of the hypoxia signaling pathway by MBNL2 in clear cell renal cell carcinoma	\$ 120,000/ 2 years <i>Funded in partnership with Canadian VHL Alliance</i> 
<i>So, Alan</i> University of British Columbia/ Vancouver Prostate Centre	YB-1 in the development of sunitinib – resistance in metastatic clear cell renal cell carcinoma	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
<i>Spatz, Alan</i> Jewish General Hospital , McGill University	Regulation of mRNA translation by PR70-PP2A in melanoma	\$ 120,000/ 2 years



2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Spicer, Jonathan</i> Research Institute of the McGill University Health Center	Immune consequences of CXCR2-mediated neutrophil recruitment to non-small cell lung cancer: Paving the way to neutrophil-based therapeutic combinations	\$ 120,000/ 2 years
<i>Stagljär, Igor</i> University of Toronto	Assessing the efficacy of newly-identified small molecule inhibitors of drug resistant EGFR triple mutants in non-small cell lung cancer	\$ 120,000/ 2 years <i>Funded in partnership with the Bergeron-Jetté Foundation</i> 
<i>Teodoro, Jose</i> McGill University	Role of triglyceride metabolism in colitis and colorectal cancer progression	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
<i>Toren, Paul</i> Université Laval	Sex steroids as modulators of the prostate cancer immune microenvironment	\$ 119,991/ 2 years


2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Trinkle-Mulcahy, Laura</i> University of Ottawa	Novel role for the prognostic indicator RepoMan in the promotion of therapeutic resistance	\$ 120,000/ 2 years <i>Funded in partnership with the University of Ottawa</i>  uOttawa
<i>Tsang, William</i> Institut de recherches cliniques de Montréal (IRCM)	Characterization of a novel Plk1 inhibitor Cep76 and its role in cancer	\$ 120,000/ 2 years
<i>Underhill, Alan</i> University of Alberta	Understanding heterochromatin phase separation in cancer	\$ 120,000/ 2 years
<i>Wallace, Valerie</i> University Health Network	Functional analysis of Norrin signaling in glioblastoma progression	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i>  CIHR IRSC Canadian Institutes of Health Research / Instituts de recherche en santé du Canada

2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Weber, Michael McGill University Health Centre	Biomedical devices for customized bone repair post surgical resection of spine metastases	\$ 117,000/ 2 years
White, John H. McGill University	Determining the vitamin D-dependent interactome of the E3 ligase and tumor suppressor FBW7	\$ 120,000/ 2 years
Wilson, Brian Princess Margaret Cancer Centre/University of Toronto	Nuclear-targeted x-ray activated photodynamic therapy of metastatic cancer	\$ 120,000/ 2 years <i>Funded in partnership with the CIHR Institute of Cancer Research</i> 
Wong, Judy The University of British Columbia / aff. BC Cancer Agency	Tumor-specific targeting of telomere with combination therapeutics	\$ 119,400/ 2 years <i>Funded in partnership with CURE Foundation</i> 

2018 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<p><i>Yamanaka, Yojiro</i> McGill University</p>	<p>Live cell extrusion and high-grade serous ovarian cancer (HGSOC) tumourigenesis in the oviduct epithelium</p>	<p>\$ 120,000/ 2 years</p> <p><i>Funded in partnership with Ovarian Cancer Canada</i></p>  <p>Ovarian Cancer Canada Cancer de l'ovaire Canada</p>
<p><i>Yu, Francois</i> Centre de recherche du Centre hospitalier de l'Université de Montréal</p>	<p>Ultrasound targeted provascular therapy for radio-sensitization of hypoxic solid tumors</p>	<p>\$ 119,449/ 2 years</p>